» Articles » PMID: 16451717

Injection Drug Use and HIV/AIDS in China: Review of Current Situation, Prevention and Policy Implications

Overview
Journal Harm Reduct J
Publisher Biomed Central
Specialties Pharmacology
Psychiatry
Date 2006 Feb 3
PMID 16451717
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Illicit drug abuse and HIV/AIDS have increased rapidly in the past 10 to 20 years in China. This paper reviews drug abuse in China, the HIV/AIDS epidemic and its association with injection drug use (IDU), and Chinese policies on illicit drug abuse and prevention of HIV/AIDS based on published literature and unpublished official data. As a major drug trans-shipment country with source drugs from the "Golden Triangle" and "Gold Crescent" areas in Asia, China has also become an increasingly important drug consuming market. About half of China's 1.14 million documented drug users inject, and many share needles. IDU has contributed to 42% of cumulatively reported HIV/AIDS cases thus far. Drug trafficking is illegal in China and can lead to the death penalty. The public security departments adopt "zero tolerance" approach to drug use, which conflict with harm reduction policies of the public health departments. Past experience in China suggests that cracking down on drug smuggling and prohibiting drug use alone can not prevent or solve all illicit drug related problems in the era of globalization. In recent years, the central government has outlined a series of pragmatic policies to encourage harm reduction programs; meanwhile, some local governments have not fully mobilized to deal with drug abuse and HIV/AIDS problems seriously. Strengthening government leadership at both central and local levels; scaling up methadone substitution and needle exchange programs; making HIV voluntary counseling and testing available and affordable to both urban and rural drug users; and increasing utilization of outreach and nongovernmental organizations are offered as additional strategies to help cope with China's HIV and drug abuse problem.

Citing Articles

The estimation of long and short term survival time and associated factors of HIV patients using mixture cure rate models.

Najafi Ghobadi K, Roshanaei G, Poorolajal J, Shakiba E, Khassi K, Mahjub H BMC Med Res Methodol. 2023; 23(1):123.

PMID: 37217850 PMC: 10201694. DOI: 10.1186/s12874-023-01949-x.


Effectiveness of a mobile-based HIV prevention intervention for the rural and low-income population involving incentive policy to doctors in Liangshan, China: a randomized controlled trial protocol.

Wang M, Liu G, Chen X, Ma S, Chen C BMC Public Health. 2022; 22(1):1682.

PMID: 36064390 PMC: 9447340. DOI: 10.1186/s12889-022-13930-2.


Independent epidemic patterns of HIV-1 CRF01_AE lineages driven by mobile population in Shenzhen, an immigrant city of China.

An M, Zheng C, Li H, Chen L, Yang Z, Gan Y Virus Evol. 2022; 7(2):veab094.

PMID: 35299786 PMC: 8923236. DOI: 10.1093/ve/veab094.


Trends of HIV, hepatitis C virus and syphilis seroprevalence among injection and non-injection drug users in southwestern China, 2010-2017.

Jiang H, Zhang X, Zhang C, Lu R, Zhou C, Ouyang L AIDS Care. 2020; 36(5):612-617.

PMID: 33345591 PMC: 10767711. DOI: 10.1080/09540121.2020.1856320.


High-risk behaviors and their association with awareness of HIV status among participants of a large-scale prevention intervention in Athens, Greece.

Pavlopoulou I, Dikalioti S, Gountas I, Sypsa V, Malliori M, Pantavou K BMC Public Health. 2020; 20(1):105.

PMID: 31992240 PMC: 6986033. DOI: 10.1186/s12889-020-8178-y.


References
1.
McGarrigle C, Mercer C, Fenton K, Copas A, Wellings K, Erens B . Investigating the relationship between HIV testing and risk behaviour in Britain: National Survey of Sexual Attitudes and Lifestyles 2000. AIDS. 2005; 19(1):77-84. DOI: 10.1097/00002030-200501030-00009. View

2.
SIMPSON D . The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry. 1979; 136(11):1449-53. DOI: 10.1176/ajp.136.11.1449. View

3.
Rosenberg H, Melville J, McLean P . Acceptability and availability of pharmacological interventions for substance misuse by British NHS treatment services. Addiction. 2002; 97(1):59-65. DOI: 10.1046/j.1360-0443.2002.00059.x. View

4.
Laeyendecker O, Zhang G, Quinn T, Garten R, Ray S, Lai S . Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr. 2005; 38(3):356-62. View

5.
Chu T, Levy J . Injection drug use and HIV/AIDS transmission in China. Cell Res. 2005; 15(11-12):865-9. DOI: 10.1038/sj.cr.7290360. View